Theravance Biopharma Inc TBPH 深 滬
已收盤 04-02 16:00:00 美东时间
16.02
+0.180
+1.14%
華盛通- 最 高16.16
- 今 開15.77
- 成交量 50.88万股
- 最 低 15.73
- 昨 收 15.84
- 總市值 8.25亿
- 52周最高 21.03
- 市盈率 靜 7.79
- 換手率 0.99%
- 52周最低 8.315
- 委 比 87.85%
- 總股本 5149.29万
- 歷史最高 43.44
- 量 比 0.84
- 振 幅 2.71%
- 歷史最低 6.10
- 每 手 1
- 風險率 3.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
Theravance Biopharma ( ($TBPH) ) has shared an update. On March 27, 2026, Thera...
03-31 07:18
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
BTIG Reiterates Buy on Theravance Biopharma, Maintains $21 Price Target
BTIG analyst Julian Harrison reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $21 price target.
03-20 18:20
Theravance Biopharma reports Q4 results
Theravance Biopharma press release (TBPH): Q4 net income was $61.0 million. Revenue of $45.9 million. Cash, cash equivalents and marketable securities totaled $326.5 million as of December 31, 2025. M...
03-20 02:54
Theravance Biopharma Q4 EPS $1.15 Beats $1.02 Estimate, Sales $45.891M Miss $50.793M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.02 by 12.75 percent. This is a 2400 percent increase over losses of $(0.05) per share from
03-19 20:37
Theravance Biopharma Q4 net income hits USD 61.02 million as total revenue rises 145% to USD 45.89 million
Theravance Biopharma Q4 net income hits USD 61.02 million as total revenue rises 145% to USD 45.89 million Theravance published a press release reporting Q4 and full-year 2025 results, including Q4 total revenue of USD 45.89 million and Q4 net income of USD 61.02 million. Viatris collaboration reven
03-19 20:32
Oppenheimer Downgrades Theravance Biopharma to Perform
Oppenheimer analyst Trevor Allred downgrades Theravance Biopharma (NASDAQ:TBPH) from Outperform to Perform.
03-06 01:59
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/downgrades, see analyst ratings page.
03-04 20:35
